--- a
+++ b/clusters/9knumclustersv2/clust_1548.txt
@@ -0,0 +1,70 @@
+Pathologically confirmed metastatic breast cancer
+Pathologically confirmed relapsed/ refractory DLBCL
+Pathologically confirmed de novo DLBCL
+Have a pathologically confirmed diagnosis of colorectal cancer, which is metastatic or otherwise unresectable
+Patients with pathologically confirmed smoldering or chronic adult T- cell leukemia as defined by Shimoyama
+Pathologically confirmed malignancy for which high-dose rate brachytherapy is appropriate as a component of their therapeutic regimen
+Pathologically confirmed NSCLC, not previously treated, with a plan to undergo surgery
+Pathologically confirmed SCCHN, not previously treated, with a plan to undergo surgery
+Have pathologically confirmed DLBCL on biopsy
+Pathologically confirmed DCIS of the breast
+Women with pathologically demonstrated breast cancer
+Pathologically confirmed MCL, with documentation of monoclonal CD+ B cells that have a chromosome translocation t(;)(q;q) and/or overexpress cyclin D.
+Patients must have pathologically confirmed advanced/metastatic cancer prior to enrollment.
+Patients must have pathologically-confirmed, previously untreated, p-positive oropharyngeal squamous cell carcinoma
+Pathologically confirmed diagnosis of cancer
+Pathologically confirmed non-small lung cancer
+Pathologically confirmed advanced solid tumor cancers
+Pathologically confirmed non-small lung cancer
+Patients with pathologically confirmed pancreatic cancer referred for image-guided radiation therapy (IGRT)
+Pathologically confirmed stage pT-T, pN, M disease
+Patients must have pathologically confirmed GIST
+Pathologically confirmed KSHV-MCD
+Have metastatic and/or unresectable pathologically confirmed well-differentiated, typical or atypical neuroendocrine tumor of the lung
+Patients must have a pathologically confirmed diagnosis, either at MSKCC or at the participating site, of stage I-III malignant pleural mesothelioma
+Patient has a radiologically and /or pathologically confirmed diagnosis of a renal tumor
+Patients with pathologically?confirmed N prostate cancer
+Pathologically confirmed diagnosis of liposarcoma; all subtypes are eligible
+Pathologically confirmed, advanced (unresectable or metastatic):
+Pathologically confirmed diagnosis of prostate adenocarcinoma
+Patients must have pathologically or radiologically confirmed metastatic disease in the brain
+Pathologically confirmed as triple negative, source documented, defined as both of the following:
+Pathologically confirmed HER-positive MBC
+Has pathologically documented breast cancer that:
+Subjects must have a pathologically confirmed diagnosis of PMF as per the WHO diagnostic criteria or post ET/PV MF;
+Pathologically confirmed MCL.
+Patients must have pathologically confirmed GIST
+The patient must have a pathologically confirmed (by histology or cytology) diagnosis of SCLC, which is currently extensive disease.
+The patient must have a pathologically confirmed diagnosis of urothelial BLC, which is currently Stage  disease.
+Patients must have pathologically confirmed GIST
+Patients must have pathologically or cytologically confirmed adenoid cystic carcinoma; cancers arising from non-salivary gland primary sites are allowed
+Pathologically confirmed adenocarcinoma of the lung.
+Adults with pathologically confirmed acute myelogenous leukemia, in pathologically confirmed complete remission; patients with refractory anemia with excess blasts- (RAEB-), who are in remission following therapy, can also be eligible
+Pathologically confirmed MCL, with documentation of monoclonal B cells that have a chromosome translocation t(;)(q;q) and/or overexpress cyclin D.
+The patient has pathologically confirmed adenocarcinoma of the prostate
+Pathologically confirmed de novo ABC DLBCL
+Patients must have pathologically or cytologically confirmed adenoid cystic carcinoma; cancers arising from non-salivary gland primary sites are allowed
+Pathologically or cytologically confirmed esophagogastric cancer
+Pathologically confirmed diagnosis of non-anaplastic non-medullary thyroid cancer that is either grossly recurrent after surgery or unresectable with or without metastatic disease
+Patient must not have pathologically N stage negative disease
+Patients must have pathologically confirmed recurrence at the time of catheter placement
+Pathologically confirmed diagnosis of breast cancer with documented progressive disease
+Patients must have pathologically-confirmed malignancy
+COHORT  ONLY: Patients must have pathologically or cytologically confirmed adenoid cystic carcinoma; cancers arising from non-salivary gland primary sites are allowed
+COHORT  ONLY: Patients must have pathologically or cytologically confirmed salivary gland cancer of any histology except for adenoid cystic carcinoma
+Kaposis sarcoma pathologically confirmed by Center for Cancer Research (CCR) pathology
+Pathologically confirmed invasive cancer of the breast
+Pathologically confirmed diagnosis of breast cancer (central confirmation is not required)
+SCLC pathologically confirmed at MSKCC
+Pathologically confirmed giant cell tumor of bone within  year before study enrollment
+Pathologically confirmed NHL
+Pathologically confirmed breast cancer
+Pathologically-confirmed solid tumor or hematologic malignancy with symptomatic bone metastases
+Has been diagnosed with localized prostate cancer (i.e. pathologically and/or radiographically confirmed)
+Has NOT been diagnosed with localized prostate cancer (i.e. pathologically and/or radiographically confirmed)
+Prospective study: individuals will have pathologically confirmed breast cancer (stages I-III)
+Retrospective chart review: Individuals will have pathologically confirmed breast cancer or gynecological (GYN) malignancies including uterine, ovarian, or cervical cancers, stages I-III; treated in the previous two years (-)
+Pathologically confirmed breast cancer
+Pathologically confirmed HER-positive breast cancer
+Pathologically confirmed diagnosis of HER positive breast cancer of any stage (previous treatment is allowed without limits on lines of prior therapy)
+Patients must either have histologic or pathologically confirmed non-small cell lung cancer (NSCLC) or suspicious nodules/lesions which are going to be surgically resected before they are pathologically confirmed